The FAVOR II China Study
Launched by CHINA NATIONAL CENTER FOR CARDIOVASCULAR DISEASES · Jun 16, 2017
Trial Information
Current as of August 27, 2025
Completed
Keywords
ClinConnect Summary
Patients at high risk of having one or more coronary stenosis are evaluated routinely by invasive coronary angiography. Lesions are often quantified by QCA, but fractional flow reserve is increasingly used to assess functional significance of identified stenosis. FFR is assessed during CAG by advancing a wire with a pressure transducer towards the stenosis and measure the ratio in pressure between the two sides of the stenosis during medical induced maximum blood flow (hyperemia).
The solid evidence for FFR evaluation of coronary stenosis and the relative simplicity in performing the measu...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- General Criteria:
- • Stable and unstable angina pectoris or secondary evaluation of stenosis after acute MI
- • Age \> 18 years
- • Able to provide signed informed consent
- Angiographic inclusion criteria:
- • At least one stenosis with diameter stenosis of 30%-90% by visual estimate
- • Reference vessel size \> 2 mm in stenotic segment by visual estimate
- Exclusion Criteria:
- General Criteria:
- • Ineligible for diagnostic intervention or FFR examination
- • Myocardial infarction within 72 hours
- • Severe heart failure (NYHA≥III)
- • S-creatinine\>150µmol/L or GFR\<45 ml/kg/1.73m2
- • Allergy to contrast agent or adenosine
- • Factors that might substantially impact the angiographic image quality, e.g, frequent atrial premature beat or atrial fibrillation
- Angiographic exclusion criteria:
- • The interrogated stenosis is caused by myocardial bridge
- • Ostial lesions less than 3 mm to the aorta
- • Side branches of the bifurcation lesions with Median Classification of 111 or 101
- • Poor angiographic image quality precluding contour detection
- • Severe overlap of stenotic segments
- • Severe tortuosity of target vessel
About China National Center For Cardiovascular Diseases
The China National Center for Cardiovascular Diseases (NCCD) is a leading research and clinical trial sponsor dedicated to advancing cardiovascular health in China and globally. As a prominent institution, NCCD focuses on innovative research, clinical management, and education in cardiovascular medicine. The center plays a crucial role in conducting rigorous clinical trials aimed at developing new therapies and improving patient outcomes for cardiovascular diseases. Through collaboration with national and international partners, NCCD is committed to enhancing the understanding of cardiovascular conditions and translating research findings into practical applications for improved healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Beijing, , China
Beijing, , China
Guangzhou, , China
Beijing, Beijing, China
Shanghai, , China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials